老年口咽癌诊疗质量指标与生存及费用的关联
该研究基于SEER-Medicare数据回顾性分析666例2004至2007年诊断的口咽鳞癌老年患者,评估指南衍生的质量指标与生存和费用的关联。结果显示更高质量诊疗与生存改善相关,但未降低总费用,且复发治疗质量与生存关系复杂,部分与姑息化疗相关。
要点
- 更高质量初治、监测及总体质量与生存改善显著相关。
- 更高质量复发治疗与生存更差相关,主要源于姑息化疗患者。
- 更高质量诊疗未降低总费用,但降低复发治疗和临终关怀的增量费用。
核心结论
- 老年口咽癌更高质量诊疗与生存改善相关,但未降低费用。
- 复发治疗质量与生存关系复杂,更高质量化疗与更差生存相关,主要因姑息化疗患者生存较差。
研究设计与样本
- 回顾性分析SEER-Medicare数据,纳入2004至2007年诊断的666例口咽鳞癌患者。
- 采用多因素回归和生存分析,基于指南推荐诊疗计算诊断、初治、监测、复发治疗、临终关怀、绩效及总体质量汇总指标。
主要发现
- 初治质量较高与生存显著改善相关(HR=0.55 [0.41至0.73])。
- 监测质量较高与生存显著改善相关(HR=0.32 [0.22至0.48])。
- 复发治疗质量较高与生存显著更差相关(HR=2.37 [1.56至3.60])。
- 绩效指标质量较高与生存显著改善相关(HR=0.50 [0.36至0.69]),总体质量汇总指标较高与生存显著改善相关(HR=0.53 [0.39至0.71])。
- 更高质量挽救手术与生存改善相关(HR=0.16 [0.04至0.54]),而更高质量复发化疗与生存更差相关(HR=5.70 [1.92至16.94])。
关键数值与推荐
- 质量指标源自指南推荐诊疗,涵盖诊断、初治、监测、复发治疗、临终关怀、绩效及总体汇总。
- 总体更高质量诊疗与费用差异无关,但与复发治疗和临终关怀的平均增量费用显著降低相关,与诊断和监测费用升高相关。
临床怎么用
- 老年口咽癌诊疗质量改进可能改善生存,但需关注复发治疗特别是姑息化疗的质量评价。
- 质量与费用关系复杂,可用于价值讨论和疾病特异性质量指标开发。
局限性
- 回顾性分析SEER-Medicare数据,证据等级2c。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine associations between quality of care, survival, and costs in elderly patients treated for oropharyngeal squamous cell cancer (OPSCC). STUDY DESIGN: Retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data. METHODS: We evaluated 666 patients diagnosed with OPSCC from 2004 to 2007 using multivariate regression and survival analysis. Using quality indicators derived from guidelines for recommended care, summary measures of quality were calculated for diagnosis, initial treatment, surveillance, treatment for recurrence, end-of-life care, performance, and an overall summary measure of quality. RESULTS: Higher-quality care was associated with significant differences in survival for initial treatment (hazard ratio [HR] = 0.55 [0.41 to 0.73]), surveillance (HR = 0.32 [0.22 to 0.48]), treatment of recurrence (HR = 2.37 [1.56 to 3.60]), performance measures (HR = 0.50 [0.36 to 0.69]), and the overall summary measure of quality (HR = 0.53 [0.39 to 0.71]). Higher-quality salvage surgery was associated with improved survival (HR = 0.16 [0.04 to 0.54]), whereas higher-quality chemotherapy given for recurrence was associated with worse survival (HR = 5.70 [1.92 to 16.94]). Overall, higher-quality care was not associated with differences in costs. Higher-quality care was associated with significantly lower mean incremental costs for treatment of recurrence and end-of-life care, and higher costs for diagnosis and surveillance. CONCLUSION: Higher-quality OPSCC care in elderly patients was associated with improved survival; however, higher-quality care was not associated with reduced costs, and higher-quality care for treatment of recurrence was associated with poorer survival, primarily due to poorer survival in patients treated with palliative chemotherapy. These data demonstrate a complex relationship between quality and costs in elderly OPSCC patients, which can be used to frame discussions of value and guide disease-specific quality-measure development. LEVEL OF EVIDENCE: 2c. Laryngoscope, 128:2312-2319, 2018.
引用
- Gourin CG, Herbert RJ, Fakhry C, et al. Quality indicators of oropharyngeal cancer care in the elderly. Laryngoscope. 2017. PMID: 29243261. doi:10.1002/lary.27050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。